Viking Therapeutics,Inc. v. Ascletis Bioscience Co., Ltd.

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA 9 VIKING THERAPEUTICS, INC., Case No.: 3:22-cv-02062-H-VET

Plaintiff,

ORDER GRANTING, IN PART, AND

v. DENYING, IN PART, RIMON, P.C.’S

MOTION TO WITHDRAW AS

ASCLETIS BIOSCIENCE CO., LTD.;

COUNSEL

GANNEX PHARMA CO., LTD.;

ASCLETIS PHARMACEUTICALS CO.,

[Doc. No. 36.] LTD.; ASCLETIS PHARMA INC.; and

JINZI JASON WU,

16 Defendants. 17 On April 3, 2023, the Court stayed the present action pursuant to 28 U.S.C. § 1659(a) pending the final decision in ITC Investigation No. 337-TA-1352. (Doc. No. 31.) On February 5, 2024, Michael F. Heafey and Matthew H. Poppe of Rimon, P.C. (“Rimon”), counsel currently representing Defendants Ascletis Bioscience Co., Ltd., Gannex Pharma Co., Ltd., Ascletis Pharmaceuticals Co. Ltd., Ascletis Pharma Inc., and Jinzi Jason Wu (collectively, “Defendants”), filed a motion to withdraw as counsel in this action for Defendants. (Doc. No. 36.) On February 23, 2024, Plaintiff Viking Therapeutics, Inc. 25 …